Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENCORE
2020-003079-16Phase 3Active
- Sponsor
- Insmed Incorporated
- Start
- Sep 2020
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amikacin in Mycobacterium avium lung disease and pneumonia (2 arms), sponsored by Insmed Incorporated. Primary endpoint: Change from Baseline to Month 13 in respiratory symptom score. Started Sep 2020; status: active.
02
Drugs
amikacin
03
Conditions
Mycobacterium avium lung diseasepneumonia
Beyond the preview
Go deeper on 2020-003079-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003079-16.